<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65541">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028338</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-023/IPM 030</org_study_id>
    <nct_id>NCT02028338</nct_id>
  </id_info>
  <brief_title>Phase 2a Study of Dapivirine Ring in Adolescent Females</brief_title>
  <official_title>Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MTN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the safety of dapivirine vaginal ring (inserted every 4 weeks)  in
      HIV-negative adolescent females
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Grade 2 AEs</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>Dapivirine ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapivirine vaginal ring (25 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ring</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>silicone vaginal ring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo ring</intervention_name>
    <arm_group_label>Placebo ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapivirine ring</intervention_name>
    <arm_group_label>Dapivirine ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 15 through 17 years (inclusive) at Enrollment, verified per site SOPs

          2. Able and willing to provide written informed assent/consent and able to obtain
             written parental or guardian permission (as specified in site SOP) to be screened for
             and to enroll in MTN-023/IPM 030

          3. Able and willing to provide adequate locator information, as defined in site SOPs

          4. Able to communicate in spoken and written English

          5. Able and willing to comply with all study procedural requirements

          6. Per participant report at Screening and Enrollment, willing to abstain from inserting
             anything into the vagina for 72 hours prior to each follow-up visit, including
             abstaining from penile-vaginal intercourse.  Note: In the event the vaginal ring has
             been expelled and requires reinsertion, repositioning the vaginal ring is permitted

          7. In general good health as determined by the Investigator of Record (IoR)/designee at
             Screening and Enrollment

          8. Assessment of onset and progression of puberty, as measured by Tanner stage 4 or 5 at
             Screening, per participant report and/or clinician assessment

          9. HIV-uninfected based on testing performed at Screening and Enrollment (per protocol
             algorithm in Appendix II)

         10. Per participant report at Screening, history of penile-vaginal intercourse (at least
             one episode in participant's lifetime)

         11. Per participant report at Screening and Enrollment, agrees to use condoms for sexual
             intercourse

         12. Negative pregnancy test at Screening and Enrollment

         13. Per participant report, using an effective method of contraception for at least 30
             days (inclusive) prior to Enrollment, and intending to continue use of an effective
             method for the duration of study participation; effective methods include:

               -  hormonal methods (except contraceptive ring)

               -  intrauterine device (IUD)

               -  sterilization (of participant, as defined in site SOPs)

         14. At Screening and Enrollment, participant states a willingness to refrain from
             inserting the following vaginal products and/or objects into the vagina; spermicides,
             diaphragms, contraceptive vaginal rings, menstrual cups, cervical caps (or any other
             vaginal barrier method), douches, lubricants, for the 5 days prior to Enrollment
             throughout the duration of study participation.  Note: Neither the use of tampons or
             sex toys, nor participant engagement in coitus is restricted.

         15. At Screening and Enrollment, agrees not to participate in other research studies
             involving drugs, medical devices, vaginal products, or vaccines for the duration of
             study participation, unless approved by the PSRT

        Exclusion Criteria:

          1. Per participant report at Screening, intends to do any of the following during the
             study participation period:

               1. become pregnant

               2. relocate away from the study site

               3. travel away from the study site for more than 4 consecutive weeks

          2. Diagnosed with a urinary tract infection (UTI) and/or reproductive tract infection
             (RTI) at Screening and/or Enrollment.  Note: Otherwise eligible participants
             diagnosed with UTI during Screening will be offered treatment and may be enrolled
             after completing treatment and all symptoms have resolved. If treatment is completed
             and symptoms have resolved within 56 days of obtaining informed consent for
             Screening, the participant may be enrolled.

          3. Diagnosed with pelvic inflammatory disease and/or an sexually transmitted infection
             (STI) requiring treatment per current Centers for Disease Control and Prevention
             (CDC) guidelines within 60 days of Enrollment (inclusive)

          4. At Enrollment, has a clinically apparent Grade 2 or higher pelvic exam finding
             (observed by study staff)** Note: Cervical bleeding associated with speculum
             insertion and/or specimen collection judged to be within the range of normal
             according to the clinical judgment of the IoR/designee is considered expected
             non-menstrual bleeding and is not exclusionary.  Note: Otherwise eligible
             participants with exclusionary pelvic exam findings may be enrolled/randomized after
             the findings have improved to a non-exclusionary severity grading or resolved. If
             improvement to a non-exclusionary grade or resolution is documented within 56 days of
             providing informed consent for screening, the participant may be enrolled.

          5. Participant report and/or clinical evidence of any of the following:

               1. Known adverse reaction to any of the study products (ever)

               2. Known HIV-infected partner

               3. Non-therapeutic injection drug use in the 12 months prior to Screening

               4. The use of HIV Post-exposure prophylaxis (PEP) and/or Pre-exposure prophylaxis
                  (PrEP) within the 6 months prior to Enrollment

               5. Currently breastfeeding

               6. Last pregnancy outcome within 90 days or less of Screening

               7. Participation in any other research study involving drugs, medical devices,
                  vaginal products, or vaccines, within 60 days of Screening

               8. Participant report of 3 or more penile-vaginal sexual partners in the month
                  prior to Screening

               9. At Enrollment, as determined by the IoR/designee, has any significant
                  uncontrolled active or chronic cardiovascular, renal, liver, hematologic,
                  neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic
                  disorder or infectious disease

          6. Has any of the following Grade 1 or higher* laboratory abnormalities at Screening
             Visit:

               1. Aspartate aminotransferase (AST) or alanine transaminase (ALT)

               2. Creatinine

               3. Hemoglobin

               4. Platelet count Note: Otherwise eligible participants with an exclusionary test
                  may be re-tested during the screening process. Please see the MTN-023/IPM 030
                  SSP for additional details.

          7. Has any other condition that, in the opinion of the IoR/designee, would preclude
             informed assent/consent, make study participation unsafe, complicate interpretation
             of study outcome data, or otherwise interfere with achieving the study objectives

               -  Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse
                  Events Version 1.0, December, 2004 (Clarification dated August 2009) **Female
                  Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS
                  Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004
                  (Clarification dated August 2009)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Faye Heard, MPH</last_name>
    <phone>2059757925</phone>
    <email>fayeh@uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB School of Medicine, Outpatient Research Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faye Heard, MPH</last_name>
      <phone>205-975-7925</phone>
    </contact>
    <investigator>
      <last_name>Craig Hoesley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
